Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Astellas Pharma Europe B.V
Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 5 ans
A PHASE II, MULTI-CENTER, OPEN-LABEL STUDY OF YM155 IN SUBJECTS WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC) PREVIOUSLY TREATED WITH AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
To evaluate the efficacy of YM155 based on the percentage of subjects that obtain a PSA response. PSA response is defined as a ≥ 50% reduction in PSA that is confirmed by a second PSA value 3 weeks a...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 5 ans
A Randomized Study comparing Placebo and ASP3652 in the treatment of women with Bladder Pain Syndrome / Interstitial Cystitis Ensayo aleatorizado comparando placebo y ASP3652 en el tratamiento de mujeres con Sindrome de Dolor Vesical/ Cistitis intersticial
To investigate efficacy of ASP3652 in female subjects with BPS/IC Investigar la eficacia del ASP3652 en mujeres con SDV/CI
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 5 ans
A study to investigate efficacy and safety of Enzalutamide in patients with hormone-naïve prostate cancer
To evaluate the effect of MDV3100 on prostate-specific antigen (PSA)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 5 ans
Efficacy and safety of Alefacept in combination with Tacrolimus, Mycophenolate Mofetil and Steroids in de-novo kidney transplantation – a multicenter, randomized, double-blind, placebo controlled, parallel group study Short Title: Proof of Concept with Alefacept in Kidney Transplantation Protocol for Phase 2 Study of Alefacept
The primary objective of this study is to evaluate the efficacy and safety of alefacept in a kidney transplant population. Data suggests that 12 weeks of treatment with alefacept in combination with t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 5 ans
A trial to investigate the efficacy of ASP7692 in patients with pain due to arthritis in the knee
Evaluate the analgesic efficacy of ASP7962 relative to placebo
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 5 ans
A randomized study comparing placebo and ASP3652 in the treatment of chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS)
To investigate efficacy of ASP3652 in subjects with CP/CPPS, i.e., obtain proof of concept.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 5 ans
A randomized, double blind, double dummy, placebo controlled study to evaluate the efficacy and safety of solifenacin succinate (5 and 10mg once daily) against placebo and oxybutynin hydrochloride (5 mg three times daily) in the treatment of subjects with neurogenic detrusor overactivity
To assess the efficacy of solifenacin 10mg compared to placebo in patients with neurogenic detrusor overactivity
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 5 ans
A Randomized, Double-Blind, Parallel Group, Active Controlled, Multicenter Long-term Study to Assess the Safety and Efficacy of the Beta-3 Agonist YM178 (50 mg qd and 100 mg qd) in Subjects with Symptoms of Overactive Bladder
To assess the safety and tolerability of long-term treatment with YM178 (50 mg qd and 100 mg qd) in subjects with symptoms of overactive bladder
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V. by August 2005)
MAJ Il y a 5 ans
A Phase II, Multicenter, Open-Label Study of YM155 in Patients With Advanced Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) Who Have Failed One or Two Prior Lines of Therapy, at Least One of Which Contained a Platinum Agent
To evaluate the efficacy of YM155 based on objective tumor response rate (CR+PR) in patients with measurable disease based on RECIST criteria
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma Europe B.V
MAJ Il y a 5 ans
A study to investigate how solifenacin fluid is taken up, how long it stays in the body and how effective and safe it is in treating children aged from 6 months to less than 5 years with symptoms of neurogenic detrusor overactivity
To evaluate the long-term efficacy, safety, and pharmacokinetics (PK) of solifenacin succinate suspension after multiple dose administration.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
5
Suivant